A recent buying spree swells 2021's meagre M&A tally, but the Pfizer-Arena deal could crystallise antitrust concerns.
The biggest biopharma deal of the year is also the biggest the Australian group has ever done.
After years of U-turns Arena's pivot to bowel disease pays off, with a $6.7bn takeout bid.
Phase 2 data with milvexian look good, but Eliquis will be a hard act to follow.
The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.